Neuraxis (NRXS) Retained Earnings (2022 - 2025)
Neuraxis (NRXS) posted Retained Earnings of $68.0 million for Q4 2025, up 208.1% sequentially from -$62.9 million in Q3 2025, and up 219.69% YoY from $21.3 million in Q4 2024.
Neuraxis (NRXS) Retained Earnings (2022 - 2025) Analysis & Trends
Neuraxis has reported Retained Earnings for 4 years, with the latest figure at $68.0 million in Q4 2025.
- Quarterly Retained Earnings rose 219.69% year-over-year to $68.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $68.0 million (up 219.69% YoY) and the FY2025 annual result came in at $68.0 million, up 219.69% from the prior year.
- Retained Earnings rose to $68.0 million in Q4 2025 per NRXS's latest filing, from -$62.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $68.0 million in Q4 2025 and troughed at -$62.9 million in Q3 2025.
- A 4-year average of $4.0 million and a median of $6.6 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings soared 238.95% in 2023, then sank 220.47% in 2024.
- Over 4 years, Retained Earnings stood at -$33.9 million in 2022, then jumped by 238.95% to $47.1 million in 2023, then tumbled by 220.47% to -$56.8 million in 2024, then jumped by 219.69% to $68.0 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered $68.0 million, -$62.9 million, and $65.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 67.99 Mn |
| Sep 30, 2025 | -62.89 Mn |
| Jun 30, 2025 | 65.01 Mn |
| Mar 31, 2025 | 59.33 Mn |
| Dec 31, 2024 | -56.80 Mn |
| Sep 30, 2024 | 53.55 Mn |
| Jun 30, 2024 | -53.60 Mn |
| Mar 31, 2024 | 47.49 Mn |
| Dec 31, 2023 | 47.15 Mn |
| Sep 30, 2023 | -46.97 Mn |
| Jun 30, 2023 | -38.34 Mn |
| Dec 31, 2022 | -33.93 Mn |